Shares of Phreesia, Inc. (NYSE:PHR – Get Rating) traded down 7.3% during mid-day trading on Friday after Raymond James lowered their price target on the stock from $55.00 to $45.00. Raymond James currently has an outperform rating on the stock. Phreesia traded as low as $26.76 and last traded at $27.23. 59 shares were traded during mid-day trading, a decline of 100% from the average session volume of 529,646 shares. The stock had previously closed at $29.38.
A number of other equities analysts have also recently commented on the company. Needham & Company LLC decreased their target price on Phreesia from $65.00 to $35.00 and set a “buy” rating on the stock in a report on Thursday. SVB Leerink decreased their price target on Phreesia from $41.00 to $29.00 and set a “market perform” rating on the stock in a report on Thursday. Royal Bank of Canada decreased their price target on Phreesia from $60.00 to $51.00 and set a “sector perform” rating on the stock in a report on Thursday, December 9th. Canaccord Genuity Group decreased their price target on Phreesia from $81.00 to $49.00 in a report on Thursday. Finally, Canaccord Genuity Group decreased their price target on Phreesia from $81.00 to $49.00 and set a “buy” rating on the stock in a report on Thursday. Four equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat.com, Phreesia has a consensus rating of “Buy” and an average target price of $52.44.
In related news, CFO Randy Rasmussen sold 2,228 shares of the business’s stock in a transaction that occurred on Wednesday, January 19th. The shares were sold at an average price of $32.66, for a total value of $72,766.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 5.60% of the company’s stock.
Hedge funds have recently modified their holdings of the company. Exane Derivatives increased its position in shares of Phreesia by 5,845.5% during the fourth quarter. Exane Derivatives now owns 654 shares of the company’s stock worth $27,000 after purchasing an additional 643 shares in the last quarter. Clearstead Advisors LLC acquired a new position in shares of Phreesia in the 3rd quarter valued at $29,000. Sageworth Trust Co of South Dakota acquired a new position in shares of Phreesia in the 4th quarter valued at $33,000. First Horizon Advisors Inc. increased its position in shares of Phreesia by 573.7% in the 4th quarter. First Horizon Advisors Inc. now owns 923 shares of the company’s stock valued at $38,000 after acquiring an additional 786 shares during the period. Finally, Advisor Group Holdings Inc. increased its position in shares of Phreesia by 63.4% in the 4th quarter. Advisor Group Holdings Inc. now owns 1,319 shares of the company’s stock valued at $55,000 after acquiring an additional 512 shares during the period. 96.10% of the stock is currently owned by institutional investors and hedge funds.
The company has a current ratio of 7.15, a quick ratio of 7.15 and a debt-to-equity ratio of 0.01. The firm has a 50-day moving average of $29.14 and a 200-day moving average of $46.88. The stock has a market capitalization of $1.40 billion, a price-to-earnings ratio of -16.91 and a beta of 1.41.
Phreesia (NYSE:PHR – Get Rating) last released its earnings results on Wednesday, March 30th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.03) by $0.33. Phreesia had a negative return on equity of 18.66% and a negative net margin of 40.51%. The firm had revenue of $58.02 million for the quarter, compared to the consensus estimate of $56.34 million. During the same period in the prior year, the firm earned ($0.18) EPS. The firm’s revenue was up 38.8% on a year-over-year basis. On average, equities research analysts anticipate that Phreesia, Inc. will post -2.49 EPS for the current year.
Phreesia Company Profile (NYSE:PHR)
Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. Its Phreesia Platform offers a suite of solutions to manage the patient intake process, as well as an integrated payments solution for processing of patient payments.